Trazodone and Weight Gain
Trazodone is considered weight-neutral and does not typically cause clinically significant weight gain. In fact, among antidepressants, it is one of the better options when weight concerns are a priority.
Evidence from Guidelines and Drug Labels
The most authoritative evidence comes from multiple clinical practice guidelines addressing pharmacotherapy for obesity. According to the 2017 Gastroenterology guideline on practical use of pharmacotherapy for obesity, within classes of antidepressants, paroxetine and amitriptyline are associated with the greatest risk for weight gain, while lithium, mirtazapine, and monoamine oxidase inhibitors are also closely associated with weight gain 1. Notably, trazodone is not listed among the weight-gaining antidepressants in these comprehensive reviews.
The 2015 Endocrine Society Clinical Practice Guideline similarly identifies specific antidepressants with weight effects: amitriptyline (1.8 kg gain), mirtazapine (1.5 kg gain), bupropion (1.3 kg loss), and fluoxetine (1.3 kg loss) 2. Again, trazodone is conspicuously absent from the list of medications causing significant weight changes.
The FDA drug label for trazodone lists "weight loss" as occurring in 1-3% of patients and "weight gain" in 1-5% of patients in controlled clinical trials 3. These rates are minimal and suggest weight neutrality rather than a consistent pattern of weight gain.
Clinical Research Supporting Weight Neutrality
Recent systematic reviews and clinical trials consistently support trazodone's weight-neutral profile:
A 2023 study specifically examining trazodone once-a-day formulation found it was "associated with low levels of sexual dysfunction and weight gain" 4
A 2019 clinical guidance review stated that trazodone "has a low risk of anticholinergic side effects, weight gain and sexual side effects" 5
A 2013 comprehensive review on weight considerations in psychotropic prescribing classified benzodiazepines, non-benzodiazepine hypnotics, doxepin, and trazodone as weight neutral 6
Multiple recent reviews (2025-2026) emphasize trazodone's "weight-neutral effects" as an advantage over other antidepressants 7, 8
Clinical Context and Practical Implications
When prescribing for patients with weight concerns:
Antidepressants to avoid due to weight gain:
- Paroxetine (highest risk among SSRIs)
- Amitriptyline (highest risk among tricyclics)
- Mirtazapine
- MAO inhibitors
Weight-neutral or weight-loss promoting alternatives:
- Trazodone (weight-neutral)
- Bupropion (promotes weight loss)
- Fluoxetine and sertraline (short-term weight loss, long-term neutral)
Common pitfall: Trazodone is often prescribed at low doses (25-75 mg) for insomnia augmentation rather than as a primary antidepressant. At these doses, any metabolic effects are even less likely to manifest. Full antidepressant dosing ranges from 150-300 mg daily 7.
The evidence consistently demonstrates that trazodone does not cause clinically meaningful weight gain and can be confidently prescribed to patients concerned about weight effects from psychotropic medications.